| Literature DB >> 25010817 |
Christina P Brötzner1, Wolfgang Klimesch2, Michael Doppelmayr3, Andrea Zauner4, Hubert H Kerschbaum5.
Abstract
Ongoing intrinsic brain activity in resting, but awake humans is dominated by alpha oscillations. In human, individual alpha frequency (IAF) is associated with cognitive performance. Noticeable, performance in cognitive and emotional tasks in women is associated with menstrual cycle phase and sex hormone levels, respectively. In the present study, we correlated frequency of alpha oscillation in resting women with menstrual cycle phase, sex hormone level, or use of oral contraceptives. Electroencephalogram (EEG) was recorded from 57 women (aged 24.07 ± 3.67 years) having a natural menstrual cycle as well as from 57 women (aged 22.37 ± 2.20 years) using oral contraceptives while they sat in an armchair with eyes closed. Alpha frequency was related to the menstrual cycle phase. Luteal women showed highest and late follicular women showed lowest IAF or center frequency. Furthermore, IAF as well as center frequency correlated negatively with endogenous estradiol level, but did not reveal an association with endogenous progesterone. Women using oral contraceptives showed an alpha frequency similar to women in the early follicular phase. We suggest that endogenous estradiol modulate resting alpha frequency.Entities:
Keywords: Center frequency; Estradiol; Individual alpha frequency; Oral contraceptive
Mesh:
Substances:
Year: 2014 PMID: 25010817 PMCID: PMC4152552 DOI: 10.1016/j.brainres.2014.06.034
Source DB: PubMed Journal: Brain Res ISSN: 0006-8993 Impact factor: 3.252
Fig. 3Estradiol level correlates negatively with alpha frequency. (A) The regression line shows a negative correlation between estradiol and center frequency in luteal woman. (B) Alpha oscillation (filtered between 7 and 14 Hz) from late follicular women having either a low estradiol or high estradiol level.
Fig. 1Average alpha center frequency (M±SD) in women with a natural menstrual cycle and women using oral contraceptives. Late follicular women show lowest center frequency. EFP: early follicular phase, LFP: late follicular phase, LP: luteal phase; pill intake phase: active phase, pill free week: inactive phase; *p<.05; **p<.01.
Women with a natural menstrual cycle.
| Age range | Mean age±SD | Mean cycle length | Schedule of studies (modus | ||
|---|---|---|---|---|---|
| Study 1 | 18 | 16–33 | 24.06±4.66 | 29.44±1.9 | September to March (December). |
| Study 2 | 19 | 19–30 | 23.32±3.45 | 27.97±2.32 | December to April (February) |
| Study 3 | 20 | 19–29 | 24.80±2.82 | 30.23±2.47 | April to October (October) |
In study 1, we excluded two women because they had no menstruation since one year and two because of technical problems. For correlational analyses between sex hormones and IAF, one subject was excluded in the late follicular and luteal phase because her estradiol level was more than two standard deviations higher than the mean. In study 2, one subject was excluded because she did not finish the study. For correlational analyses between sex hormones and IAF one subject was excluded in the early follicular and one subject in the late follicular phase because their estradiol level was more than two standard deviations higher than the mean. Furthermore, one subject was excluded in the late follicular and luteal phase and one subject in the luteal phase because their progesterone level was more than two standard deviations higher than the mean. In study 3, one woman was excluded during luteal phase because of inadequate determination of luteal phase. For correlational analyses between sex-hormones and IAF we excluded one participant in each cycle phase because her saliva sample was contaminated with lipstick. One woman was excluded during late follicular and luteal phase because her progesterone level was more than two standard deviations higher than the mean. Furthermore, we had one missing values of progesterone level during early follicular phase because it was too high and, therefore, not quantifiable.
modus: month, in which most women were studied.
Women using oral contraceptives (combination pill).
| N | Age range | Mean age±SD | Oral contraceptives | Schedule of studies (modus | |
|---|---|---|---|---|---|
| Study 1 | 17 | 19–26 | 22.53±2.27 | Desogestrel ( | October to March (January) |
| Study 2 | 20 | 18–26 | 21.60±2.19 | Desogestrel ( | November to March (January) |
| Study 3 | 20 | 20–28 | 23±2.03 | Desogestrel ( | April to October (July) |
Combined oral contraceptive pill contained ethinylestradiol (.015–.035 mg) and different doses of progestins. In study 1, two women were excluded because they use different hormonal contraceptives then the classical combined contraceptive pill and other three because of technical problems. In study 2, one subject was excluded because she did not finished the study. For correlational analyses between sex-hormones and IAF one subject was excluded during pill intake and pill free week because her progesterone level was more than two standard deviations higher than the mean. In study 3, one subject was excluded because she did not finished the study. One more participant was excluded because she is a diabetic and need to regularly inject insulin. For correlational analyses between sex-hormones and IAF two participants were excluded during pill free week because their progesterone level were more than two standard deviations higher than the mean. Furthermore we had one missing values of progesterone level during pill intake phase because it was too high and therefore impossible to measure.
modus: month, in which most women were studied.
Mean±SD for estradiol- (E2) and progesterone-level (P) (in pg/ml) for early follicular phase (EFP) late follicular phase (LFP) and luteal phase (LP).
| EFP | LFP | LP | ||||
|---|---|---|---|---|---|---|
| P | P | P | ||||
| Study 1 | ||||||
| Study 2 | ||||||
| Study 3 | ||||||
Mean±SD for estradiol- (E2) and progesterone-level (P) (in pg/ml) for pill intake phase and pill free week.
| Pill intake phase | Pill free week | |||
|---|---|---|---|---|
| P | E2 | P | ||
| Study 1 | ||||
| Study 2 | ||||
| Study 3 | ||||